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Background. Tuberculin skin testing (TST) and preventive treatment of tuberculosis (TB) are recommended
for all persons with human immunodeficiency virus (HIV) infection. We aimed to assess the effect of TST and
preventive treatment of TB on the incidence of TB in the era of combination antiretroviral therapy in an area
with low rates of TB transmission.
Methods. We calculated the incidence of TB among participants who entered the Swiss HIV Cohort Study
after 1995, and we studied the associations of TST results, epidemiological and laboratory markers, preventive TB
treatment, and combination antiretroviral therapy with TB incidence.
Results. Of 6160 participants, 142 (2.3%) had a history of TB at study entry, and 56 (0.91%) developed TB
during a total follow-up period of 25,462 person-years, corresponding to an incidence of 0.22 cases per 100 person-
years. TST was performed for 69% of patients; 9.4% of patients tested had positive results (induration 5 mm
in diameter). Among patients with positive TST results, TB incidence was 1.6 cases per 100 person-years if preventive
treatment was withheld, but none of the 193 patients who received preventive treatment developed TB. Positive
TST results (adjusted hazard ratio [HR], 25; 95% confidence interval [CI], 11–57), missing TST results (HR, 12;
95% CI, 4.8–20), origin from sub-Saharan Africa (HR, 5.8; 95% CI, 2.7–12.5), low CD4+ cell counts, and high
plasma HIV RNA levels were associated with an increased risk of TB, whereas the risk was reduced among persons
receiving combination antiretroviral therapy (HR, 0.44; 95% CI, 0.2–0.8).
Conclusion. Screening for latent TB using TST and administering preventive treatment for patients with positive
TST results is an efficacious strategy to reduce TB incidence in areas with low rates of TB transmission. Combination
antiretroviral therapy reduces the incidence of TB.
Coinfection with tuberculosis (TB) and HIV is one of
the world’s biggest health problems [1]. HIV infection
facilitates reactivation of latent TB. On the other hand,
TB-induced immune activation may lead to faster pro-
gression of HIV infection [2, 3]. In resource-poor coun-
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tries, TB is among the most frequent and devastating
opportunistic infections among HIV-infected individ-
uals. Migrants from these regions contribute to the bur-
den of TB in Switzerland before and during the era of
combination antiretroviral therapy (cART) [4, 5].
Tuberculin skin testing (TST) is considered to be part
of routine care for HIV-infected persons [6, 7], despite
the limited sensitivity and specificity of the test [8–11].
A PPD test with an induration of 5 mm is an indi-
cation for preventive treatment of latent TB [6]. This
recommendation is based mainly on studies conducted
before the cART era that were performed in areas with
a high prevalence of latent TB [12–15]. Sensitivity of
TST may be markedly reduced among HIV-infected
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Table 1. Demographic and clinical characteristics of study patients.
Variable
No TB
(n p 5962)
Prevalent TB
(n p 142)
Incident TB
(n p 56)
Total
(n p 6160) P
Percentage of total patients 96.8 2.3 0.91 100
Female sex 31 40 50 32 .001
Age, median years (IQR) 36 (30–43) 34.5 (28–42) 31.5 (28–39) 36 (30–43) !.001
Median CD4+ cell count at registration (IQR) 330 (174–528) 167 (83–295) 248 (118–348) 326 (170–518) .001
CD4+ cell count !200 cells/mL at registration 28.8 58.5 39.3 29.6 .001
Median log10 plasma HIV RNA level at registration (IQR) 4.3 (3.1–5.0) 4.2 (2.6–5.3) 4.7 (4.1–5.3) 4.3 (3.0–5.0) .04
Region !.001
Low-risk region 81.0 44.4 37.5 79.7
Medium-risk region 7.2 7.8 14.3 7.3
Sub-Saharan Africa 11.8 47.9 48.2 13.0
Transmission !.001
HET 42.0 71.1 73.2 43.0
IDU 20.3 16.9 14.3 20.2
MSM 33.5 5.6 8.9 32.6
Other or unknown 4.2 6.3 3.6 4.2
Health care provider !.001
Main centers 73.4 76.8 89.0 73.6
HIV clinics in smaller hospitals 5.9 14.1 1.8 6.0
Private physicians 20.73 9.2 8.9 20.4
Receipt of ART at registration 40.5 57.0 28.6 40.83 !.001
Receipt of cART at registration 33.4 52.1 19.6 33.7 !.001
NOTE. Data are % of patients, unless otherwise indicated. ART, antiretroviral therapy; cART, combination antiretroviral therapy; HET, heterosexual transmission;
IDU, injection drug use; IQR, interquartile range; MSM, men who have sex with men; TB, tuberculosis.
patients with low CD4+ cell counts [16, 17]. An evaluation
within the Swiss HIV Cohort Study (SHCS) prior to the in-
troduction of cART has shown a significantly increased adjusted
relative risk of 5.5 for persons with a positive TST result and
CD4+ cell counts 1200 cells/mL [4]. We aimed to assess the
effect of TST and preventive therapy on the incidence of TB
in the cART era in a geographic area with a low rate of TB
transmission.
METHODS
The SHCS
The SHCS (http://www.shcs.ch) is a prospective observational
study of HIV-infected individuals performed at HIV outpatient
clinics at 5 university hospitals and 2 large district hospitals
[18]. At study enrollment and every 6 months thereafter, so-
ciodemographic, clinical, and laboratory information is col-
lected. Treatment of HIV infection and of opportunistic infec-
tions is documented.
Guidelines recommend performing TST for all patients
within 1 year after registration by injecting 0.1 mL of tuberculin
(2 U of PPD RT-23) intradermally on the forearm. Documented
TSTs performed before registration are also entered into the
database. An induration diameter of 5 mm defines a positive
TST result according to the recommendations of the American
Thoracic Society [19].
Study Participants and Definitions
For the present analysis, all participants entering the SHCS after
1 January 1996 were considered. We used the database updated
in February 2006. Three groups of patients were defined: (1)
the “no TB” group, which included patients without a history
of TB and who did not develop TB during follow-up; (2) the
“prevalent TB” group, which included patients with a history
of TB before entering the SHCS; and (3) the “incident TB”
group, which included patients with incident active TB during
follow-up within the SHCS.
Regions of origin were regrouped according the prevalence
of TB into (1) sub-Sahara Africa; (2) medium-risk regions,
including Eastern Europe, Central Asia, North Africa and the
Middle East, South Asia, East Asia, and the Caribbean; and (3)
low-risk regions. Preventive treatment of latent TB infection
was defined as treatment with isoniazid for at least 24 weeks,
rifampicin or rifabutin for at least 16 weeks, or a combination
of rifampicin or rifubutin together with pyrazinamide for at
least 8 weeks. cART was defined as antiretroviral treatment with
at least 3 antiretroviral drugs.
Study Design and Statistical Analysis
Prevalence of TB. Associations of prevalent TB with socio-
demographic factors were evaluated with multivariable logistic
regression.
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Figure 1. Proportion of patients with positive tuberculin skin test (TST)
results according to CD4+ cell count stratum at the time of TST (P !
for trend statistics)..001
Table 2. Logistic regression models of associations with positive tuberculin skin test (TST) results.
Variable
Univariate analysis
(n p 3681)
Mulitvariate model
(n p 3681)
Multivariate model
(n p 1056)
Crude OR (95% CI) Adjusted OR (95% CI) P Adjusted OR (95% CI) P
Sub-Saharan Africa vs. low-risk region 4.68 (3.68–5.95) 5.58 (3.88–8.01) !.001 4.76 (2.40–9.45) !.001
Medium-risk region vs. low-risk region 2.05 (1.43–2.95) 2.36 (1.54–3.62) !.001 1.91 (0.828–4.42) .1
Female sex 1.17 (0.94–1.46) 0.59 (0.44–0.80) !.001 0.52 (0.29–0.92) .3
Heterosexual HIV transmission vs. MSM 2.07 (1.59–2.69) 1.48 (1.03–2.12) .04 2.18 (1.06–4.48) .03
IDU HIV transmission vs. MSM 1.29 (0.92–1.81) 1.63 (1.10–2.42) .01 2.74 (1.22–6.14) .01
Other/unknown HIV transmission vs. MSM 3.03 (1.93–4.74) 2.23 (1.27–3.91) .005 3.68 (1.35–10.0) .01
Age per 10-year increase 0.80 (0.71–0.89) 1.02 (0.89–1.17) .8 1.15 (0.89–1.49) .3
CD4+ cell count at TST per 100-cell/mL increase 1.21 (1.17–1.26) 1.23 (1.17–1.28) !.001 1.02 (0.88–1.18) .8
Plasma HIV RNA level at TST per log10 copies/mL
increase 0.87 (0.82–.092) 0.84 (0.77–0.92) !.001 0.91 (0.78–1.07) .3
Triple ART at TST 0.66 (0.52–0.84) 0.42 (0.29–0.60) !.001 0.65 (0.33–1.27) .2
Nadir CD4+ cell count before TST per 100-cell/mL
increase 1.30 (1.18–1.43) … 1.30 (1.08–1.56) .006
NOTE. The multivariate models included only patients with all parameters available and included all parameters in the table. The multivariate model with
1056 participants included all patients with a documented nadir CD4+ cell count before TST and before initiation of antiretroviral therapy. ART, antiretroviral therapy;
IDU, injection drug use; MSM, men who have sex with men.
Prevalence of positive TST results. Data about TST results
were analyzed with regard to epidemiological parameters, in-
cluding history of TB, region of origin, CD4+ cell count, and
receipt of concurrent cART.
Incidence of TB. The incidence of TB in the SHCS was
evaluated assuming a Poissson distribution of events. Associ-
ation of incidence with epidemiological parameters and TST
results and history of treatment of latent TB were analyzed
using Kaplan Meier curves, log-rank statistics, and multivari-
able Cox proportional hazards models, including start of an-
tiretroviral therapy with at least 3 drugs as a time-dependent
covariate, splitting follow-up time accordingly. The propor-
tional hazards assumptions in Cox models were tested on the
basis of Schoenfeld residuals, and they had to be fulfilled for
each covariate.
RESULTS
Patient Characteristics
Among 6160 SHCS participants who entered the SHCS after
1 January 1996, 142 (2.3%) had a history of TB, and 56 (0.91%)
developed new active TB during follow-up. Three patients with
history of TB before registration received a diagnosis of re-
current TB during follow-up. These patients were excluded
from the analyses of TB incidence. The patient characteristics
are shown in table 1. The differences in baseline characteristics
are because of the predominant presumed heterosexual HIV
transmission mode, younger age, and higher number of female
subjects among patients from regions of higher TB endemicity.
History of TB at Registration
A history of TB at registration was found in 142 (2.3%) of the
patients. HIV infection was documented in 65 (46%) of these
142 patients after the diagnosis of TB and in 53 (37%) within
1 year after TB diagnosis. Forty-four (68%) of the participants
with a diagnosis of TB before documented HIV infection were
from sub-Sahara Africa.
Patients with a history of TB at registration had lower CD4+
cell counts and were more likely to be receiving cART when
entering the SHCS (table 1). This paradoxical finding can be
explained by the lower nadir CD4+ cell counts in patients who
started cART and had a history of TB (median CD4+ cell count,
88 cells/mL), compared with the TB-free patients (median CD4+
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Figure 2. A, Kaplan Meier curve of the proportion of participants remaining free of tuberculosis (TB) according their region of origin ( , byP ! .001
log rank test). B, Kaplan Meier curves according to whether a tuberculin skin test (TST) had been performed and according to the results of the TST.
The participants with a positive TST result were grouped according to whether they had received a full course of preventive therapy against latent
TB infection ( , by log rank test).P ! .001
cell count, 216 cells/mL; ), whereas duration of cARTP ! .001
or plasma viral load were not significantly different between
these 2 groups. In a logistic model, the adjusted OR (aOR) for
the association of epidemiological factors with a history of TB
at registration were female sex (aOR, 0.58; 95% CI, 0.40–0.84;
), age per 10-year increase (aOR, 1.0; 95% CI, 0.85–Pp .004
1.20; ), and sub-Saharan African origin, compared withPp .8
origin from a low-risk region (aOR, 5.7; 95% CI, 3.6–8.9;
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Table 3. Incidence of tuberculosis (TB) according to tuberculin skin test (TST) results and
region of origin among patients who did not receive preventive treatment.
Variable
No. of
incident
TB cases
No. of
persons at risk
No. of
person-years
of follow-up
Incidence per
100 person-years
(95% CI)
Low-incidence countries
All results 21 4756 20,929 0.10 (0.06–0.15)
Positive TST result 5 158 726 0.69 (0.22–1.61)
Negative TST result 5 3098 15,791 0.03 (0.01–0.07)
Missing TST result 11 1500 4543 0.24 (0.12–0.43)
Medium-incidence countries
All results 8 420 1581 0.51 (0.22–1.00)
Positive TST result 2 23 75 2.67 (0.32–9.64)
Negative TST result 2 267 1185 0.17 (0.02–0.61)
Missing TST result 4 130 322 1.24 (0.34–3.17)
Sub-Saharan Africa
All results 27 651 2084 1.30 (0.85–1.89)
Positive TST result 9 65 203 4.42 (2.02–8.40)
Negative TST result 3 379 1540 0.19 (0.04–0.57)
Missing TST result 15 207 407 3.69 (2.06–6.08)
All patients
All results 56 5827 24,593 0.23 (0.17–0.30)
Positive TST result 16 246 1005 1.59 (0.91–2.59)
Negative TST result 10 3744 18,516 0.05 (0.03–0.10)
Missing TST result 30 1837 5273 0.57 (0.38–0.81)
). HIV transmission modes by heterosexual sex (aOR,P ! .001
6.1; 95% CI, 2.8–13.3; ) and injection drug use (aOR,P ! .001
5.9; 95% CI, 2.6–13.2; ) were associated with a historyP ! .001
of TB, compared with transmission associated with men who
have sex with men.
TST
A TST was performed for 4168 (69%) of the 6018 patients
without a history of TB at entry, and 390 (9.4%) of those who
were tested had positive results. TST had been performed for
only 26 (46%) of the 56 patients who developed TB during
follow-up, and 16 (62%) had positive results.
Adherence to recommendation of TST. The percentage of
participants tested in the different centers was 32.5%–87.8%
( ). There was no difference in adherence to TST forP ! .001
patients of different origin (68.9% of patients from low-risk
regions, 70.2% of patients from medium-risk regions, and
71.3% of patients from sub-Saharan Africa were tested). TST
was performed more frequently among patients with CD4+ cell
counts at registration of !200 cells/mL (72.2%) than among
patients with CD4+ cell counts 200 cells/mL (68.1%; Pp
) and less frequently among patients receiving cART at.002
registration than among those not receiving cART (63.6% vs.
72.1%; ).P ! .001
In a multivariable logistic model including the region of
origin, individual SHCS center, CD4+ cell count stratum, cART
at registration, sex, presumed HIV transmission mode, and age,
TST was performed significantly less often at certain individual
centers, for patients with an HIV transmission mode of injec-
tion drug use, and for patients receiving cART at registration.
Associations with positive TST results. Positive TST results
were highly associated with CD4+ cell count at the time of TST
(figure 1). Results of a logistic regression model of associations
with positive TST results are shown in table 2. In the multi-
variate model, a positive TST result was associated with origin
from a region with higher TB prevalence, male sex, HIV trans-
mission mode other than men who have sex with men, higher
CD4+ cell counts, and lower plasma HIV RNA levels. Receiving
cART was associated with a lower rate of positive TST results
if analyzed for all patients with available TST results.
In a subset of 1051 patients for whom nadir CD4+ cell counts
before TST were available, lower nadir CD4+ cell counts were
strongly associated with negative TST results. In this model
with less power, the point estimate of the adjusted ORs for
plasma HIV RNA level, CD4+ cell count, and receipt of cART
at the time of TST moved towards 1, and the respective as-
sociations did not reach statistical significance.
Preventive Treatment of TB Infection
Preventive treatment of latent TB infection was administered to
193 participants and consisted of isoniazid in 149 (77%), rifa-
butin combined with pyrazinamide in 30 (16%), rifabutin in 7
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Figure 3. Results of a Cox proportional hazards model of developing tuberculosis during follow-up. The model included all of the variables shown.
Bars, 95% CI. ART, antiretroviral therapy; HR, hazard ratio; IDU, injection drug use; TST, tuberculin skin test.
(4%), rifampicin combined with pyrazinamide in 4 (2%), and
rifampicin alone in 3 (1.5%). Two of these participants had a
history of active and treated TB. Among 390 patients with a
positive TST results, 144 (37%) received a full course of treat-
ment, as did 13 with missing TST data and 34 with negative TST
results. No participant who started a full course of preventive
treatment developed TB during follow-up. Among the 246 par-
ticipants with a positive TST result who did not receive preventive
treatment, 16 (6.5%) developed active TB.
Performance of TST and Numbers Needed to Treat with
Preventive Therapy
We evaluated the performance of TST with regard to the de-
velopment of active TB in 4034 patients who did not receive
any preventive therapy. Ten (0.26%) of 3778 participants with
a negative TST result developed TB, compared with 6.5% of
246 participants with a positive TST result. Therefore, the sen-
sitivity of the test was 62.5%, the specificity was 94.3%, the
positive likelihood ratio was 10.7, the negative likelihood ratio
was 0.41, the positive predictive value was 6.5%, and the neg-
ative predictive value was 99.7%. The corresponding area under
the receiver operating characteristic curve was 0.82.
Assuming a full protection of preventive treatment, in our
patient population, we would need to treat 15 patients with
positive TST results (95% CI, 10–27 patients) to prevent 1 case
of TB. The corresponding numbers for participants from
regions with medium or high prevalence of TB were 8 patients
(95% CI, 5–15 patients) and 33 patients (95% CI, 14–97 pa-
tients), respecitvely.
Incidence of TB
Fifty-six participants (0.91%) developed TB during a total fol-
low-up of 25,462 person-years, corresponding to an overall
incidence of 0.22 cases per 100 person-years (95% CI, 0.17–
0.29 cases per 100 person-years). The median duration of fol-
low-up was 52 months (interquartile range, 23–85 months).
Thirty-three patients (59%) developed pulmonary TB, 18
(32%) developed extrapulmonary TB, and 5 (9%) developed
combined pulmonary and extrapulmonary disease. The median
CD4+ cell count at TB diagnosis was 208 cells/mL (interquartile
range, 112–354 cells/mL).
The Kaplan Meier curves in figure 2A show the strong as-
sociation between the incidence of TB and the region of origin
of the participants. Data regarding the development of TB ac-
cording to TST results and whether preventive treatment of
latent TB was prescribed for patients with positive TST results
are illustrated in figure 2B. No participant who received pre-
ventive treatment developed TB. The risk of TB was higher for
participants with a positive TST result and participants who
had not been tested, compared with participants with negative
TST results.
The incidences for TB among patients who did not receive
preventive treatment differed according to TST results and the
region of origin. These data are shown in table 3.
In a multivariate Cox proportional hazards model, the hazard
of TB was highly increased in patients originating from regions
with higher TB endemicity and in participants with positive or
missing TST results. Higher plasma HIV RNA levels and lower
CD4+ cell counts remained associated with a higher risk. Start
of antiretroviral therapy with at least 3 drugs included as time-
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dependent variable splitting the follow-up was associated with
reduction of the risk of TB by more than one-half (figure 3).
CONCLUSION
In a country with a low endemicity of TB, and in the era of
cART, the region of origin was a major predictor of a history
of TB in our cohort of HIV-infected patients and was associated
with the risk of developing TB. A positive TST result was also
related to a considerably higher risk of TB. Preventive therapy
of latent TB was highly successful. In addition, starting anti-
retroviral therapy was associated with a significant reduction
in the risk of developing TB.
The strength of our study is its use of a large, comprehensive
prospective database that is representative of the epidemiology
of HIV infection and the state of HIV care in our country. This
allows the analyses of TB incidence, even in the context of low
rates of TB transmission in the cART era. Limitations include
the potential underestimation of the TB incidence because of
a short follow-up of !2 years duration for one-quarter of our
patients and the delay between diagnosis of HIV infection or
TB and registration in the SHCS, which results in more patients
entering the cohort with a history of TB than patients devel-
oping the disease during follow-up.
TST. HIV infection is associated with a20-fold increased
risk for reactivation of latent TB, both in resource-poor and
resource-rich countries [20, 21]. Therefore, identifying HIV-
infected persons with latent TB infection and treating them
with preventive chemotherapy has been included in most treat-
ment recommendations [2, 6] and has been found to be suc-
cessful mainly in countries with high rates of TB transmission
[12, 13, 22]. Until recently, TST has been the standard test to
identify persons with latent TB. However, the sensitivity of this
test is reduced with progressing immunodeficiency in patients
with HIV infection [16], and the specificity of the test may be
low, especially in countries with a high proportion of persons
who have received bacille Calmette-Gue´rin vaccine [23]. This,
and the difficulties of organizing this 2-visit procedure, may
have led to the surprisingly low rate of adherence of 70% to
the recommendation for TST testing. We found a high differ-
ence in adherence with regard to the different centers in which
the patients received treatment, indicating the importance of
local priorities in HIV care.
In concordance with the lower sensitivity of the TST in im-
munosuppressed patients, we found a lower proportion of pos-
itive TST results in patients with lower CD4+ cell counts. Sur-
prisingly, we found a lower proportion of positive TST results
among patients who were receiving antiretroviral treatment at
the time of TST. This could be explained by the lower nadir
CD4+ cell count before TST in this subset of patients. The nadir
CD4+ cell count seems to be an important predictor of TST
reactivity, and antiretroviral treatment may partly, but not fully,
reconstitute skin reactivity to tuberculin antigens [24–26]. On
the other hand, the high rate of positive TST results (15%) in
patients with CD4+ cell counts 500 cells/mL points towards
a considerable number of false-positive TST results, as has been
shown in Switzerland in non–HIV infected individuals [23],
and this has been related to the high rate of bacille Calmette-
Gue´rin vaccination.
Incidence of TB. The overall incidence of 0.2 cases per 100
person-years is one of the lowest reported thus far for HIV-
infected adults, and it is even lower than the rates recently
reported by the antiretroviral therapy cohort collaboration for
patients receiving combination antiretroviral therapy [27].
However, our data tend to underestimate the real incidence of
TB in HIV-infected persons in our country, because TB was
diagnosed in 2.3% of the patients before they entered our co-
hort, and TB was the marker illness for the diagnosis of HIV
infection in a high proportion of participants. This was espe-
cially the case for patients from regions associated with a high
risk of TB transmission. The origin of the patients, however,
remained a major predictor of development of TB.
In addition, patients with a positive TST result had a hazard
ratio of 25 for the development of TB (compared with partic-
ipants with negative TST results) if they were not receiving
preventive therapy. Preventive treatment of latent TB was highly
successful in our setting. The high success rate associated with
preventive therapy points towards a good adherence to therapy
once it was initiated and may have been facilitated by the low
rate of drug resistance and the low rate of TB transmission in
our country. Reinfections are a likely explanation for the failure
of preventive therapy in areas with high rates of TB transmis-
sion [28, 29], but they are rare in Switzerland. On the other
hand, nonadherence of physicians to preventive therapy was a
significant risk factor for incident TB. Only 37% of patients
with positive TST results received a full course of preventive
treatment. Fear of adverse effects and concerns about false-
positive TST results may have led physicians and their patients
to this decision.
On the basis of our results, 15 persons would need to be
treated to prevent 1 case of active TB in our patient population.
The number of patients who would need to be treated to pre-
vent 1 case of TB was only 8 for migrants from regions as-
sociated with a higher risk of TB, but it increased to 33 for
participants from regions with low rates of TB transmission.
These findings clearly favor the prescription of preventive treat-
ment, especially for participants originating from areas asso-
ciated with a high or medium risk of TB transmission. Whether
the introduction of the more-specific IFN-based assays to detect
latent TB infection would reduce the number of patients who
would need to be treated to prevent 1 case of TB needs to be
investigated [30–32].
A higher grade of immunodeficiency at registration was as-
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sociated with an increased risk of TB, reflecting a higher re-
activation rate [33, 34]. We analyzed the influence of cART by
splitting the follow-up of participants into the phase before and
after start of cART. We found a significantly reduced hazard
ratio of 0.44 of incident TB among patients during the period
after the start of cART. cART-associated immune reconstitution
has been found to reduce TB incidence in other cohorts, even
in areas with high rates of TB transmission [34], and it rein-
forces calculations about the importance of antiretroviral ther-
apy for TB control [35, 36].
We conclude that screening for latent TB using TST and
preventive treatment for patients with positive TST results re-
mains an efficacious strategy to reduce TB-associated morbid-
ity, even in the cART era, in a country with low rates of TB
transmission. This is especially important for patients origi-
nating from regions with high TB-infection rates. cART reduces
the incidence of TB significantly.
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